Dr. Reddy's Q3FY26 Revenues at ₹87,268 Mn, Profit Attributable to Equity Holders at ₹12,098 Mn
Dr. Reddy's Laboratories reported Q3FY26 consolidated revenues of ₹87,268 million, up 4.4% YoY. Profit attributable to equity holders was ₹12,098 million, down 14% YoY. Key developments include a strategic collaboration with Immutep and new drug launches in India. The company also announced Science-Based Net Zero Climate Targets.
The results provide a mixed financial performance with revenue growth but profit decline. Strategic partnerships and new product launches indicate future growth potential, but regulatory challenges and specific market performance warrant a medium impact assessment.
While revenues showed year-on-year growth, profits declined. Several new product launches and strategic collaborations were positive, but regulatory setbacks for biosimilars and a decline in North America Generics temper the overall sentiment.
Dr. Reddy's Laboratories Limited announced its unaudited financial results for the quarter and nine months ended December 31, 2025. The consolidated revenues for the third quarter of fiscal year 2026 (Q3FY26) stood at ₹87,268 million, marking a 4.4% year-on-year increase and a 0.9% quarter-on-quarter decrease. For the nine months ended December 31, 2025 (9MFY26), consolidated revenues grew by 8.4% year-on-year to ₹260,771 million.
Profit after tax attributable to equity holders for Q3FY26 was ₹12,098 million, a 14% decrease year-on-year and a 16% decrease quarter-on-quarter. For 9MFY26, this profit remained flat year-on-year at ₹40,649 million. The company reported EBITDA of ₹20,493 million for Q3FY26, a 11% decrease year-on-year, and ₹66,788 million for 9MFY26, a 1% decrease year-on-year.
Key business highlights for the quarter included a strategic collaboration with Immutep for an immunotherapy oncology drug, the launch of Hevaxin® in India, and receiving marketing authorization for Semaglutide injection in India. The company also made progress on biosimilar candidates, receiving European Commission approval for denosumab biosimilar and launching it in Germany. However, it also received Complete Response Letters from the US FDA for denosumab and rituximab biosimilar BLAs.
ESG highlights include the announcement of Science-Based Net Zero Climate Targets by FY2045, leadership in CDP categories, and receiving the CII Award of Merit for waste minimization. The company also achieved certifications for Net Positive Water Impact and was recognized as one of India's Top 100 Great Places to Work.
What to do with a filing like this
Dr. Reddy's Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Dr. Reddy's Laboratories Limited. Read the original for the full detail.